Vaccines

The Democratic of the Congo Ministry of Health has authorized the use of 5 experimental Ebola treatments as more than 100 cases of Ebola are reported.

A new study reveals that the quadrivalent HPV catch-up vaccine was most effective against cancer risk in women who received the first dose between the ages of 14 and 20 years.

A total of 107 cases of measles has been reported thus far this year in the United States and the District of Columbia, underscoring the importance of vaccination.

Several outbreaks of mumps in university settings throughout Indiana in 2016 highlight a need for standardized immunization record collection and a third MMR vaccination dose for individuals at increased risk of infection.

In case you missed them, we’ve compiled the top 5 infectious disease articles from this past week.

An experimental HIV-1 vaccine regimen reportedly produced immune responses against HIV in humans and rhesus monkeys.

Varying dose levels of the GEN-003 vaccine were found to be associated with decreased viral shedding and lesion reduction at up to 1 year post-treatment.

Stay up-to-date on the latest infectious disease news by reading the top 5 articles of the week.

Hepatitis A outbreaks that have been crippling states across the nation since March of 2017 continue to wreak havoc in several cities.

A recent study finds that shortening the rabies pre-exposure prophylaxis regimen is both effective and safe.

Experts continue to recommend that people get the seasonal flu vaccine as the scientific community works toward a universal vaccine offering lifelong protection against multiple strains.

A reported case of the deadly disease was a misdiagnosis, but it is still a warning sign of the troubles facing the South American country.

Researchers are calling for an end to nonmedical exemptions for vaccines in the 18 states that still allow them, saying several metropolitan areas are now vulnerable to measles outbreaks.

Single-dose vaccines delivered via a new technology platform may offer full protection against Zika, Lassa fever, and Ebola.

Xingmin Sun, PhD, shares current progress on developing a vaccine for Clostridium difficile infection.

Xingmin Sun, PhD, discusses aspects that need to be considered before developing a vaccine for Clostridium difficile.

Anne Schuchat, MD, provides some history and insights on CDC’s role in safeguarding public health when the microbial world collides with the human world.

The overall rate of health care personnel receiving flu shots has gone up in recent years, but a new study finds that much of the increase is due to policies held at non-VA hospitals.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

The Vaccine Adverse Event Reporting System reveals a number of errors made in the administration of the new shingles vaccine.

Stopping polio transmission will require addressing persistent challenges to vaccinating every child.

Despite public health recommendations, a new study has found that too many adolescents and young adults in the United States are failing to complete the full vaccination course for HPV.

Following recent reports that England has seen more measles cases so far in 2018 than in all of 2017, health officials are combating outbreaks of the virus with vaccination clinics.

Researchers have found that a vaccine for Junin virus, a South American hemorrhagic fever virus, protects against another virus in the same family, opening up the possibility for universal vaccines for virus families.

In case you missed them, we've compiled the top 5 articles from this past week.

A phase 2 trial of an experimental universal flu vaccine is moving forward with sponsorship from The National Institute of Allergy and Infectious Diseases.

Novavax announces that enrollment in phase 3 Prepare trial has reached approximately 4,600 participants, of whom, at least 3,000 have received the RSV F vaccine.

If clinical development progresses, the PaxVax vaccine could potentially become the first vaccine approved by the FDA for the prevention of chikungunya.

A recent study has found that a single-dose of Merck's Ebola vaccine delivers antibodies that can last for 1 to 2 years.

If this indication is approved, physicians will be able to reserve the vaccine for young children to protect them against the 2019-2020 flu season.